The license includes stable cell lines for investigating and screening calcium channels and applicable small molecule modulators developed in the lab of Dr. Yubin Zhou. These cell lines have a number of uses including the blocking of CRAC channels to suppress immune system response during organ transplant and autoimmune diseases as well as provide a screening process that saves on chemicals, incubation time, and washing steps to accelerate HTS Assays. The agreement also includes canine osteosarcoma and osteoblastic cell lines, developed by Dr. Heather Wilson-Robles, which are often used with in vitro and murine models of cancer research. This is particularly valuable given the cell lines ability to develop potential human cancer therapies given the degree of similarity between canine and human osteosarcoma cancers. Lastly, included in the license is an immortalized Myok9 cell line developed by Dr. Peter P. Nghiem. This cell line permits the research of canine skeletal muscle and is more comparable to humans that the currently existing mouse models, with the added benefit of being the first commercially available immortalized canine myoblast cell line. This partnership will make the cell lines available for use in a variety of applications, and we look forward to seeing the potential impact these innovations can have in both the research and commercial settings.
Media Contact: Jennifer Briggs